The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Effect of Tilarginine Acetate in Patients With Acute Myocardial Infarction and Cardiogenic Shock: The TRIUMPH Randomized Controlled Trial
Open accessAbstract
CONTEXT: Cardiogenic shock complicating acute myocardial infarction (MI) remains a common and lethal disorder despite aggressive use of early revascularization. Systemic inflammation, including expression of inducible nitric oxide synthase (NOS) and generation of excess nitric oxide, is believed to contribute to the pathogenesis and inappropriate vasodilatation of persistent cardiogenic shock. Preliminary, single-center studies suggested a beneficial effect of NOS inhibition on hemodynamics, renal function, and survival in patients with cardiogenic shock. OBJECTIVE: To examine the effects of an isoform-nonselective NOS inhibitor in patients with MI and refractory cardiogenic shock despite establishment of an open infarct artery. DESIGN, SETTING, AND PATIENTS: International, multicenter, randomized, double-blind, placebo-controlled trial (Tilarginine Acetate Injection in a Randomized International Study in Unstable MI Patients With Cardiogenic Shock [TRIUMPH]) with planned enrollment of 658 patients at 130 centers. Participants were enrolled between January 2005 and August 2006 when the study was terminated early. INTERVENTION: Tilarginine (L-N(G)-monomethylarginine [L-NMMA]), 1-mg/kg bolus and 1-mg/kg per hour 5-hour infusion, vs matching placebo. MAIN OUTCOME MEASURES: The primary outcome was 30-day all-cause mortality among patients who received study medication. Secondary outcomes included shock resolution and duration, New York Heart Association (NYHA) functional class at 30 days, and 6-month mortality. RESULTS: Enrollment was terminated at 398 patients based on a prespecified futility analysis. Six-month follow-up was completed in February 2007. There was no difference in 30-day all-cause mortality between patients who received tilarginine (97/201 [48%]) vs placebo (76/180 [42%]) (risk ratio, 1.14; 95% confidence interval, 0.92-1.41; P = .24). Resolution of shock (133/201 [66%] tilarginine vs 110/180 [61%] placebo; P = .31) and duration of shock (median, 156 [interquartile range, 78-759] hours tilarginine vs 190 [100-759] placebo; P = .16) were similar. At 30 days a similar percentage of patients had heart failure (48% tilarginine vs 51% placebo; P = .51) with a similar percentage of those patients in NYHA class I/II (73% tilarginine vs 75% placebo; P = .27). After 6 months mortality rates were similar in the 2 groups (58% tilarginine vs 59% placebo; hazard ratio, 1.04; 95% confidence interval, 0.79-1.36; P = .80). CONCLUSIONS: Tilarginine, 1-mg/kg bolus and 5-hour infusion, did not reduce mortality rates in patients with refractory cardiogenic shock complicating MI despite an open infarct artery. Early mortality rates in this patient group are high. Further research is needed to develop effective therapies for patients with cardiogenic shock following acute MI. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00112281
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Management of acute myocardial infarction in patients presenting with ST-segment elevation
VandeWerf, F. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00618-8 · Cited by 1,448
López, A., Lorente, J. A., Steingrub, J., Bakker, J., McLuckie, A., Willatts, S., Brockway, M., Anzueto, A., Holzapfel, L., Breen, D., et al. (2004) · Critical Care Medicine · doi:10.1097/01.ccm.0000105581.01815.c6 · Cited by 921
Hochman, J. S., Sleeper, L. A., Webb, J. G., Dzavik, V., Buller, C. E., Aylward, P., Col, J., White, H. D., & SHOCK Investigators, F. T. (2006) · JAMA · doi:10.1001/jama.295.21.2511 · Cited by 710
Babaev, A., Frederick, P. D., Pasta, D. J., Every, N., Sichrovsky, T., Hochman, J. S., & NRMI Investigators, F. T. (2005) · JAMA · doi:10.1001/jama.294.4.448 · Cited by 667
Arnold, J. M. O., Liu, P., Demers, C., Dorian, P., Giannetti, N., Haddad, H., Heckman, G. A., Howlett, J. G., Ignaszewski, A., Johnstone, D. E., et al. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70237-9 · Cited by 415
Smith, S. C., Jr. (2019) · PubMed · doi:10.17615/vf9y-es17 · Cited by 184
L-NMMA (a Nitric Oxide Synthase Inhibitor) is Effective in the Treatment of Cardiogenic Shock
Cotter, G., Kaluski, E., Blatt, A., Milovanov, O., Moshkovitz, Y., Zaidenstein, R., Salah, A., Alon, D., Michovitz, Y., Metzger, M. W., et al. (2000) · Circulation · doi:10.1161/01.cir.101.12.1358 · Cited by 141
Lessons Learned From Recent Cardiovascular Clinical Trials: Part II
DeMets, D. L., & Califf, R. M. (2002) · Circulation · doi:10.1161/01.cir.0000023220.26465.89 · Cited by 122
Lessons Learned From Recent Cardiovascular Clinical Trials: Part I
DeMets, D. L., & Califf, R. M. (2002) · Circulation · doi:10.1161/01.cir.0000023219.51483.66 · Cited by 104
Dauerman, H. L., Goldberg, R. J., White, K., Gore, J. M., Sadiq, I. R., Gurfinkel, E., Budaj, A., de Sá, E. L., & Lopez-Sendon, J. L. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02704-2 · Cited by 103
Cited by
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Authors/Task Force Members, Steg, P. G., James, S. K., Atar, D., Badano, L. P., Lundqvist, C. B., Borger, M. A., Di Mario, C., Dickstein, K., Ducrocq, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs215 · Cited by 6,829
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock
Thiele, H., Zeymer, U., Neumann, F.-J., Ferenc, M., Olbrich, H.-G., Hausleiter, J., Richardt, G., Hennersdorf, M., Empen, K., Fuernau, G., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208410 · Cited by 2,861
van Diepen, S., Katz, J. N., Albert, N. M., Henry, T. D., Jacobs, A. K., Kapur, N. K., Kilic, A., Menon, V., Ohman, E. M., Sweitzer, N. K., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000525 · Cited by 1,869
Metadata
- Authors
- The TRIUMPH Investigators*
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2007-04-18
- Volume
- 297
- Issue
- 15
- Pages
- 1657
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1209933684
- Cited by
- 400
- References
- 14
- FWCI
- 20.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Tilarginine Acetate in Patients With Acute Myocardial Infarction and Cardiogenic Shock: The TRIUMPH Randomized Controlled Trial. https://app.cochat.ai/papers/10.1001/jama.297.15.joc70035
- The paper
- The TRIUMPH Investigators*. (2007). Effect of Tilarginine Acetate in Patients With Acute Myocardial Infarction and Cardiogenic Shock: The TRIUMPH Randomized Controlled Trial. JAMA. https://doi.org/10.1001/jama.297.15.joc70035
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.